The Role of Nestin in Glioblastoma Prognosis
Author Information
Author(s): Chinnaiyan Prakash, Wang Meihua, Rojiani Amyn M, Tofilon Philip J, Chakravarti Arnab, Ang K Kian, Zhang Hua-Zhong, Hammond Elizabeth, Curran Walter Jr, Mehta Minesh P
Primary Institution: H. Lee Moffitt Cancer Center and Research Institute
Hypothesis
Does nestin expression have prognostic value in newly diagnosed glioblastoma patients?
Conclusion
The study found that nestin expression does not significantly correlate with overall survival or progression-free survival in newly diagnosed glioblastoma patients.
Supporting Evidence
- 153 out of 156 samples were evaluable for the study.
- There were no statistically significant differences in overall survival or progression-free survival based on nestin expression levels.
- 12-month survival rates were 59% for low, 49% for intermediate, and 48% for high nestin expression.
Takeaway
This study looked at a protein called nestin in brain cancer patients and found it doesn't help predict how long they will live or how well they will do after treatment.
Methodology
Tissue microarrays were prepared from 156 patients, stained for nestin, and analyzed for expression levels using computerized image analysis.
Potential Biases
The cohort may be biased towards patients with more complete resections, potentially skewing the results.
Limitations
The study's findings may not be applicable to all glioblastoma patients due to the retrospective nature of the tissue samples and the treatments used being from the pre-temozolomide era.
Participant Demographics
{"gender":{"male":64,"female":36},"race":{"white":144,"hispanic":3,"black":5,"other":1}}
Statistical Information
P-Value
0.06
Statistical Significance
p = 0.06
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website